It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Learn how online tools can help you efficiently find investment opportunities. Simplify your investment search with technology.
22,540 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Oracle slipped this year, but does that mean it's a no-brainer AI buy? This practical guide weighs AI potential, fina...
When cultural moments go big, your wallet pays attention. This article breaks down how Pink and Queen Latifah are exp...
A sudden fire in New Jersey claimed Paul Avery and his wife, a reminder that solid financial planning safeguards love...
A Father's Day post from Kris Jenner shines a spotlight on blended families, ex-partners and wealth. Here's what it t...
A hypothetical chair kevin warsh $6.7 balance sheet presents a tough puzzle for policy and markets. This article brea...
A clear, investor-focused read on what The Trade Desk's Q1 2026 results mean for 2026. Discover growth drivers, margi...
Former Goldman Sachs CEO Lloyd Blankfein warns that AI operates with speed but limited verifiability, a risk that cou...
Artificial intelligence is reshaping how we build and defend crypto networks. Discover the ideas behind AI-assisted v...
A New York City bar is testing a novel hedge: using Kalshi's prediction markets to manage revenue risk tied to Knicks...
A growing alliance between Alphabet and Anthropic could redefine how AI is trained and deployed. This piece breaks do...
Investors often ask where will fluor stock head next. This guide lays out base, bull, and bear scenarios, plus concre...